Cancer Gene Therapy

Cancer Gene Therapy is a monthly peer-reviewed journal published by Springer Nature under the Nature Portfolio imprint, founded in 1994, covering gene therapy and cell therapy in cancer research and treatment, with a 2025 Journal Impact Factor of 6.4（Cancer Gene Therapy）是（Springer Nature）旗下（Nature Portfolio）出版的月刊同行评审期刊，1994 年创刊，涵盖癌症研究与治疗中的基因治疗与细胞治疗，2025 年影响因子为 6.4。

Scope

• It describes itself as the essential gene and cellular therapy resource for cancer researchers and clinicians该刊自称是面向癌症研究人员与临床医生的基因与细胞治疗核心资源。
• It covers gene-transfer technologies and viral and non-viral delivery systems该刊涵盖基因转移技术以及病毒与非病毒递送系统。
• Its scope includes RNA interference, cancer vaccines and tumour immunology其范围包括 RNA 干扰、癌症疫苗与肿瘤免疫学。
• It publishes on immunotherapy and cellular therapies, including CAR-T cell therapy该刊发表免疫治疗与细胞治疗（含 CAR-T 细胞治疗）研究。
• Other topics include cancer stem cells, tumour-suppressor genes, drug resistance, apoptosis and DNA synthesis and repair其它主题包括癌症干细胞、肿瘤抑制基因、耐药、细胞凋亡与 DNA 合成与修复。
• It welcomes basic science, bioengineering and biophysical approaches, bioinformatics and mathematical modelling, translational studies, systemic therapies and clinical trials该刊欢迎基础科学、生物工程与生物物理方法、生物信息学与数学建模、转化研究、系统治疗与临床试验。
• Article types include articles, review articles, brief communications, case reports, industry perspectives and letters to the editor文章类型包括论文、综述、短讯、病例报告、行业观点与读者来信。

History

• The journal was founded in 1994 by the founding editors Robert E. Sobol and Kevin J. Scanlon as a Nature Publishing Group journal该刊于 1994 年由创始编辑 Robert E. Sobol 与 Kevin J. Scanlon 创办，为（Nature Publishing Group）期刊。^[1]
• Steven K. Libutti served as editor-in-chief for about six years, and under his leadership the journal marked its twenty-fifth anniversary in 2019 with an anniversary collectionSteven K. Libutti 任主编约六年，在其任内该刊于 2019 年以二十五周年文集纪念创刊二十五周年。
• Georgios Giamas became editor-in-chief in 2020 and set out a vision and strategy for the new decadeGeorgios Giamas 于 2020 年出任主编，并提出新十年的愿景与战略。
• Submissions rose from 142 in 2017 to 359 in 2019, and the two-year impact factor rose from 4.044 in 2018 to 4.681 in 2019投稿量由 2017 年的 142 篇增至 2019 年的 359 篇，两年影响因子由 2018 年的 4.044 升至 2019 年的 4.681。^[2]
• Leandro Castellano of the University of Sussex became editor-in-chief on 1 January 2026（University of Sussex）的 Leandro Castellano 于 2026 年 1 月 1 日出任主编。
• Its impact factor was 5.0 in 2024 and 6.4 in 2025其影响因子 2024 年为 5.0，2025 年为 6.4。

Editors

• The editor-in-chief is Leandro Castellano, reader in RNA biology at the University of Sussex, who took office on 1 January 2026现任主编 Leandro Castellano 为（University of Sussex）RNA 生物学高级讲师，2026 年 1 月 1 日就任。
• He obtained his PhD in human biology and genetics from the University of Rome La Sapienza and has held academic positions at Imperial College London and the University of Sussex他在（University of Rome La Sapienza）获人类生物学与遗传学博士学位，曾在（Imperial College London）与（University of Sussex）担任学术职务。
• His research focuses on microRNAs and non-coding RNAs in the development and progression of epithelial cancer其研究聚焦 microRNA 与非编码 RNA 在上皮癌发生发展中的作用。
• Georgios Giamas, his predecessor, led the journal from 2020 to 2025, and Steven K. Libutti before him from about 2013 to 2019前任主编 Georgios Giamas 于 2020 至 2025 年领导该刊，此前的 Steven K. Libutti 约自 2013 年任至 2019 年。
• Manuscripts are submitted only through the online submission system, and pre-submission enquiries are directed to the editorial office稿件仅经在线投稿系统提交，投稿前咨询请联系编辑部。
• Review is single anonymized, the editorial office performs an initial quality check, and since 2026 first submissions must include a cover letter on institutional letterhead, institutional e-mail addresses and an author contribution statement评审为单盲方式，编辑部先进行质量初审，且自 2026 年起首次投稿须附机构信头的投稿信、机构电子邮箱与作者贡献声明。